Smart materials that read the heart’s oxidative stress could transform cardiac therapy

When blood flow returns to a oxygen-starved heart after a heart attack, the paradox of modern cardiology unfolds: the very act of reperfusion that rescues starving muscle also floods it with a barrage of destructive molecules known as reactive oxygen species. A sweeping new review published in Frontiers in Drug Delivery argues that this chaotic chemical environment, far from being merely an obstacle, could be harnessed as a precision delivery system — a molecular trigger that tells smart biomaterials exactly when and where to release their healing cargo. The synthesis, which critically evaluated 100 preclinical studies of reactive oxygen species-responsive and redox-modulating biomaterials, arrives at a sobering but hopeful verdict: the science is mechanistically compelling, but not a single human trial has yet been conducted.

The biological logic behind these materials is rooted in the peculiar geography of a heart attack. Oxidative stress after ischemia-reperfusion injury is neither uniform nor static. It surges in the acute reperfusion phase, subsides during inflammatory resolution, and then resurges as scar formation and ventricular remodeling proceed over weeks to months. It also differs sharply between the injury core and the surrounding border zone. The review’s authors point out that this spatial and temporal heterogeneity creates a natural opening for delivery systems that exploit pathological redox conditions as a cue — releasing drugs preferentially where oxidative stress is fiercest, or degrading on a schedule that matches the evolving stages of repair.

Not everything marketed as ROS-responsive actually behaves that way, the review cautions. Some platforms use reactive oxygen species as an active trigger, cleaving thioketal, boronic ester, Schiff-base, or disulfide bonds to initiate drug release or matrix degradation. Others simply scavenge ROS, catalytically convert reactive species, deliver antioxidants to mitochondria, generate oxygen, or modulate endogenous antioxidant pathways. Demonstrating that treatment lowers oxidative stress is not proof of stimulus-responsive behavior. True responsiveness requires quantitative evidence that oxidative conditions alter a measurable material property — cleavage rate, degradation, or release kinetics — ideally compared against matched low-ROS or non-responsive controls.

The strongest quantitative examples in the literature illustrate what genuine responsiveness looks like. Core-shell microgels carrying salvianolic acid B and candesartan showed hydrogen-peroxide-accelerated release, with candesartan reaching 68 percent release over 21 days in oxidative conditions versus just 24 percent in neutral buffer. Another hydrogel, loaded with apelin-13, released its cargo faster in the high-ROS injury core and more slowly in the lower-ROS border zone of the same infarcted heart, directly coupling spatial redox gradients to drug availability. These systems treat the pathological environment as a delivery instruction rather than merely a therapeutic target — a genuine step toward spatiotemporally controlled cardiovascular medicine.

Four major platform classes dominate the field, each with distinct trade-offs. Injectable hydrogels and microgels offer high local retention and staged release but typically require invasive intramyocardial injection, limiting routine clinical applicability. Systemic nanoparticles and liposomes can be given intravenously during the narrow peri-reperfusion window and can incorporate tissue-, cell-, or organelle-level targeting, but their value hinges on quantitative biodistribution and clearance data that most studies have not provided. Catalytic nanozymes — ceria-based particles, single-atom iron, copper, and manganese catalysts, and bimetallic PtIr systems — promise sustained ROS detoxification rather than stoichiometric antioxidant consumption, but raise questions about inorganic persistence, particle transformation, and long-term safety.

Mitochondrial targeting emerges as a particularly coherent precision strategy, because mitochondria sit at the center of reperfusion injury — generating ROS, opening permeability transition pores, and orchestrating regulated cell death through apoptosis, ferroptosis, pyroptosis, and cuproptosis. In a landmark mouse study, cyclosporine A-loaded nanoparticles that localized to cardiac mitochondria reduced infarct size at lower drug concentrations than free drug and improved 28-day ventricular remodeling — notably without altering inflammatory monocyte recruitment. That finding carries a broader mechanistic lesson: cardiac benefit does not require suppressing every inflammatory compartment, and the relationship between redox control, mitochondrial protection, and inflammation is platform-dependent rather than universally linear.

Reading the therapeutic numbers requires discipline, the review insists. Treated left ventricular ejection fractions of roughly 49 to 52 percent across several studies look impressively similar, but they come from different models, routes, controls, and time points, and cannot be cross-ranked. The most informative designs are matched comparisons that isolate a single design feature: responsive hydrogel versus non-reactive gel, targeted nanoparticle versus untargeted, intramyocardial injection versus epicardial patch — the latter showing that delivery geometry alone changed cardiac outcomes even when payload was identical. One porcine study, the only explicitly identified large-animal investigation, reported that a ROS-eliminating miR-19a/b hydrogel shrank infarct size from 40 to 18 percent, with all treated pigs surviving to scheduled harvest at 50 days.

The translational gap, however, is stark. Of the 74 primary cardiac studies, 57 were explicitly mouse, rat, or murine experiments; only one extended to pigs; and no human observational or trial evidence was identified anywhere in the evidence base. Comprehensive pharmacokinetics, whole-organ biodistribution, carrier-versus-payload clearance, repeated-dose tolerability, and platform-specific toxicology were inconsistently reported. Cardiovascular safety deserves special scrutiny — few studies performed systematic QT/QTc analysis, chronic rhythm monitoring, or delayed-arrhythmogenicity assessment, even though these materials lodge in electrically vulnerable myocardium. Encouraging preliminary tolerability signals, the authors warn, should not be conflated with comprehensive safety characterization.

The review also questions whether escalating complexity serves patients. A membrane-coated, mitochondria-targeted nanozyme carrying a nucleic-acid payload demands vastly more identity, purity, stability, and reproducibility controls than a simple acellular carrier, and manufacturing evidence — GMP-compatible scale-up, sterilization, shelf life, batch-release specifications — was largely absent from the literature. The most clinically credible platform, the authors argue, may not be the most multifunctional one but the minimum-complexity system that delivers sufficient drug to the right myocardial compartment at the right disease stage, with measurable benefit over a simpler comparator and a plausible regulatory pathway.

The path forward, the authors conclude, requires six commitments: standardized definitions of ROS responsiveness; head-to-head comparator studies under identical models; disease-stage-matched experiments; integrated pharmacokinetic and biodistribution analysis; platform-specific long-term cardiovascular safety; and rigorous large-animal and manufacturing development. They also envision a precision-medicine dimension — because clinical infarcts vary in duration, reperfusion success, and comorbidities, and one circadian study found efficacy varied with time-of-day injury severity, future systems may need biomarkers or imaging to identify which patients and myocardial regions actually possess the redox conditions that activate responsive materials. Until then, ROS-responsive cardiovascular biomaterials remain what the review calls them: mechanistically promising but clinically unproven precision-delivery technologies whose value will be decided by whether sophisticated chemistry can become standardized, safe, scalable therapy.

Subject of Research: ROS-responsive biomaterials for precision drug delivery in myocardial ischemia-reperfusion injury and post-infarction remodeling

Article Title: Engineering the oxidative myocardium: ROS-responsive biomaterials for precision cardiovascular delivery in ischemia-reperfusion injury and post-infarction remodeling

Article References: Omidian, H., Mfoafo, K. A., & Cubeddu, L. X. (2026). Engineering the oxidative myocardium: ROS-responsive biomaterials for precision cardiovascular delivery in ischemia-reperfusion injury and post-infarction remodeling. Frontiers in Drug Delivery, 6, Article 1929035. https://doi.org/10.3389/fddev.2026.1929035

Image Credits: AI Generated

DOI: 10.3389/fddev.2026.1929035

Keywords: ROS-responsive biomaterials, myocardial ischemia-reperfusion injury, post-infarction remodeling, reactive oxygen species, drug delivery, hydrogels, nanoparticles, nanozymes, mitochondrial targeting, cardiac repair, oxidative stress, preclinical research